Let's not forget that OncoImmune put out a press release 9/24 saying they had been stopped for efficacy at 203 of 270 targeted, with "P=.005" on an "alive and unintubated" endpoint. Lots of data in the release - referred to as "top-line results."

Shortly after, the press release was withdrawn and the web site says they are "nearing completion" of the study.

What happened? Could we have a p-value like that?

https://www.biospace.com/article/releases/onc...-covid-19/